Xlife Sciences AG: Successful first half of 2024 with strategic progress and solid financial figures | 19.09.24

Zurich, September 19, 2024: Xlife Sciences AG (SIX: XLS) today published its half-year report 2024 and announced significant progress in its business development. Despite a challenging market environment, the company was able to further expand its innovative strength and promote new partnerships and developments within its diversified portfolio.

The complete 2024 Half-Year Report of Xlife Sciences AG is available for download as a PDF document in the «Financial Reports» section at https://www.xlifesciences.ch/en/news-and-key-figures. Operational Highlights in the First Half of 2024 Xlife Sciences AG’s diversified portfolio includes 25 project companies, which made significant progress during the reporting period. The following highlights are exemplary:

• x-nuclear diagnostics GmbH: With the introduction of the innovative PET tracer DAZAmed, promising results in liver diagnostics in humans were achieved. The rollout of the tracer is planned for the third quarter of 2024.
• VERAXA Biotech AG: The company has complemented its portfolio with an exclusive license in the field of hemibody technology, in addition to successful preclinical tests. This significantly reduces the risks of side effects and high toxicity in cancer therapy.
• novaxomx GmbH: Positive results from tests with extracellular vesicles to promote bone growth represent an important step towards market readiness.
• FUSE-AI GmbH: The market launch of the AI ​​software «Prostate.Carcinoma.ai» has been successfully completed and improves the speed and accuracy of prostate cancer diagnosis. More indications, such as breast or lung cancer, are expected to follow soon.
• palleos healthcare GmbH: The strategic merger with OCT Clinical GmbH strengthens the position in clinical research and opens up access to additional countries and regions.

In addition, significant synergies between portfolio companies were exploited to promote technological innovations and open new market segments. More information on this can be found in the letter to our shareholders in the Half-Year Report.

Financial figures

In the first half of 2024, Xlife Sciences generated sales of CHF 349,818 (previous year: CHF 347,979). Earnings per share amounted to CHF 0.08 (previous year: CHF -1.10). The balance sheet total increased to CHF 509.9 million (previous year: CHF 477.9 million) and equity reached CHF 367.0 million (previous year: CHF 332.6 million).

Strategic partnerships and internationalization

Another focus in the first half of 2024 was the internationalization of the business, notably through expanded collaboration in Abu Dhabi with partners such as Thermo Fisher Scientific and Masdar City. These partnerships strengthen Xlife Sciences’ position as a leading player in life sciences and clinical research on a global scale.

Outlook for the second half of 2024

Xlife Sciences is optimistic about the second half of the year and plans further strategic milestones. Two thirds of the portfolio has reached the “Proof of Concept” status, which provides a solid basis for future growth.

Oliver R. Baumann, CEO of Xlife Sciences AG, commented: «Despite a challenging market environment, we were able to make significant progress in the first half of 2024. Our innovative projects and strategic partnerships create sustainable value for our shareholders. We are well positioned to achieve further growth and value enhancement in the long term»

Financial calendar